Want to see TSE:MDMA full AI Analyst Report?
Top Page
PharmAla Biotech Holdings, Inc.
(MDMA)
Select Model
Select Model
Rating:52Neutral
Price Target:
C$0.24
▲(7.73% Upside)
Action:Reiterated
Date:08/22/26
The score is primarily held back by weak financial fundamentals—ongoing operating losses and negative free cash flow despite improving revenue growth—while the debt-free balance sheet provides some offset. Technicals are supportive due to an uptrend above major moving averages, but elevated RSI/Stoch suggests momentum may be stretched. Valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Improving revenue growth
Improving revenue indicates increasing commercial traction and customer activity compared with the prior annual period. If growth continues, greater scale could help absorb the company’s high operating cost structure and provide a foundation for improving margins over time.
Negative Factors
Persistent unprofitability
Negative gross profit and large operating losses show that current revenue is not covering the cost base, limiting the durability of earnings. The business therefore needs substantial operating improvement or much greater scale before revenue growth can translate into sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue growth
Improving revenue indicates increasing commercial traction and customer activity compared with the prior annual period. If growth continues, greater scale could help absorb the company’s high operating cost structure and provide a foundation for improving margins over time.
Read all positive factors
PharmAla Biotech Holdings, Inc. (MDMA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$25.67M
Dividend YieldN/A
Average Volume (3M)226.48K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth224.46%
EPS Growth28.37%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding109,236,030
10 Day Avg. Volume151,402
30 Day Avg. Volume226,481
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model
Company Description
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. T...
How the Company Makes Money
PharmAla’s revenue model is primarily based on supplying pharmaceutical-grade MDMA (and potentially other related compounds) to authorized customers such as clinical trial sponsors, research institutions, and other regulated entities. The company ...
PharmAla Biotech Holdings, Inc. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.27M | 605.50K | 1.04M | 532.00K | 78.07K | 0.00 |
| Gross Profit | -310.49K | -845.17K | 887.44K | 454.10K | 75.78K | -303.00 |
| EBITDA | -1.47M | -2.07M | -573.36K | -710.18K | -973.45K | -2.51M |
| Net Income | -1.61M | -2.18M | -823.60K | -779.81K | -985.58K | -2.51M |
Balance Sheet | ||||||
| Total Assets | 3.07M | 3.42M | 2.90M | 2.41M | 2.33M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 245.06K | 960.66K | 419.38K | 195.04K | 852.14K | 2.47M |
| Total Debt | 0.00 | 0.00 | 0.00 | 253.54K | 0.00 | 0.00 |
| Total Liabilities | 1.14M | 961.73K | 916.88K | 1.03M | 423.78K | 138.48K |
| Stockholders Equity | 1.93M | 2.46M | 1.98M | 1.38M | 1.91M | 2.66M |
Cash Flow | ||||||
| Free Cash Flow | -993.75K | -1.05M | -547.78K | -846.39K | -1.62M | -435.76K |
| Operating Cash Flow | -968.53K | -1.04M | -321.36K | -339.66K | -625.37K | -173.57K |
| Investing Cash Flow | 925.31K | -935.27K | -226.42K | -506.74K | -994.87K | 629.22K |
| Financing Cash Flow | 6.95K | 1.60M | 772.12K | 189.29K | 0.00 | 2.02M |
PharmAla Biotech Holdings, Inc. Technical Analysis
Positive
0.22
Price Trends
0.17
Positive
0.16
Positive
0.13
Positive
Market Momentum
0.02
Positive
60.54
Neutral
22.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDMA, the sentiment is Positive. The current price of 0.22 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.17, and above the 200-day MA of 0.13, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 22.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDMA.
PharmAla Biotech Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | C$25.67M | -15.77 | -72.15% | ― | 224.46% | 28.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$15.95M | -20.83 | 10.15% | ― | ― | -36.36% | |
46 Neutral | C$7.60M | -0.44 | -48.52% | ― | -13.00% | 75.31% | |
39 Underperform | C$5.01M | -4.55 | -155.46% | ― | ― | 26.95% |
* Healthcare Sector Average
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.24
0.12
113.64%
TSE:CSCI
COSCIENS Biopharma
7.63
-2.90
-27.59%
TSE:PREV
PreveCeutical Medical
0.03
-0.01
-28.57%
TSE:PHRM
PharmaTher Holdings Ltd
0.06
-0.32
-85.33%
PharmAla Biotech Holdings, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
PharmAla Biotech Wins U.S. Patent, Retains APA-01 Rights and Hires Canaccord
Positive
Aug 21, 2026
PharmAla Biotech has secured a U.S. patent covering novel processes for manufacturing single enantiomers of MDMA and MBDB, a step the company says will improve the economics of producing R-MDMA and its non-racemic ALA-002 formulation while strengt...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.